Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial

被引：0
|
作者：
Gao, Qinglei
Wang, Jing
Xu, Qin
Tang, Ying
Zhang, Jieqing
Chang, Baoping
Xia, Bairong
Duan, Wei
Wang, Danbo
Zhu, Lijing
An, Ruifang
Zhang, Guonan
Tang, Yaling
Huang, Jianli
Zhang, Xiang
Qiu, Hui
Ji, Wenting
Li, Li
Zhu, Jianqing
Ma, Ding
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT079
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
    Que, Yi
    Wang, Juan
    Sun, Feifei
    Wang, Shan
    Zhu, Jia
    Huang, Junting
    Zhao, Zhenzhen
    Zhang, Li
    Liu, Juan
    Xu, Jiaqian
    Zhen, Zijun
    Sun, Xiaofei
    Lu, Suying
    Zhang, Yizhuo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [2] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
    Yi Que
    Juan Wang
    Feifei Sun
    Shan Wang
    Jia Zhu
    Junting Huang
    Zhenzhen Zhao
    Li Zhang
    Juan Liu
    Jiaqian Xu
    Zijun Zhen
    Xiaofei Sun
    Suying Lu
    Yizhuo Zhang
    Signal Transduction and Targeted Therapy, 8
  • [3] Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
    O'Malley, David M.
    Oaknin, Ana
    Monk, Bradley J.
    Selle, Frederic
    Rojas, Carlos
    Gladieff, Laurence
    Berton, Dominique
    Leary, Alexandra
    Moore, Kathleen N.
    Estevez-Diz, Maria D. P.
    Hardy-Bessard, Anne-Claire
    Alexandre, Jerome
    Opperman, Christina P.
    de Azevedo, Carla Rameri A. S.
    Randall, Leslie M.
    Feliu, Waldo Ortuzar
    Ancukiewicz, Marek
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 274 - 280
  • [4] Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial
    Wan, T.
    Huang, H.
    Feng, Y.
    Zheng, M.
    Li, J.
    Huang, Q.
    Liu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1508 - S1508
  • [5] Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial
    Wan, Ting
    Huang, He
    Feng, Yanling
    Li, Jundong
    Zheng, Min
    Meng, Yifan
    Liu, Jihong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.
    Zhou, Caicun
    Xiong, Anwen
    Li, Wei
    Wang, Lei
    Wu, Fengying
    Yu, Jia
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Wang, Wenxiang
    Zhuang, Wu
    Yang, Jun
    Sun, Jiya
    Wang, Hongli
    Liu, Ying
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study
    Liu, Jiayong
    Tan, Zhichao
    Fan, Zhengfu
    Bai, Chujie
    Xue, Ruifeng
    Li, Shu
    Gao, Tian
    Zhang, Lu
    Wang, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
    Xu, Qin
    Chen, Chuan-ben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
    Xu, Nong
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Xiong, Anwen
    Li, Wei
    He, Yayi
    Ren, Shengxiang
    Wang, Lei
    Yu, Jia
    Zhu, Jun
    Liu, Ying
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
12345